This report aims to guide experts, communicators and practitioners to communicate with impact, so that the public understands and supports action on drug-resistant infections.
[Summary] This report aims to help experts and practitioners to communicate with impact, so that the public understands and supports action on drug-resistant infections.
This paper examines the status, progress and challenges in research and development for epidemics. It was developed to feed into the first annual report of the Global Preparedness Monitoring Board.
Key outcomes from the second Call to Action on Antimicrobial Resistance held in Ghana, co-hosted by the Governments of Ghana, Thailand and the UK, along with the World Bank, UN Foundation and Wellcome.
This scientific white paper looks at the evidence about how antimicrobial resistance in the environment is impacting human health, and at how the risks can be addressed. It summarises discussions from the International Environmental AMR forum, held in April 2018.
A summary of the findings of our scientific white paper, which looks at the evidence about how antimicrobial resistance in the environment is impacting human health, and at how the risks can be addressed.
Recommendations from a pilot project to openly publish human antimicrobial resistance surveillance data generated and collected by the pharmaceutical industry. The project was led by the Open Data Institute and funded by Wellcome.
summary of the discussions at the forum, which looked at opportunities to better understand and help reduce the impact of environmental AMR on human health.
The key outcomes from the Call to Action on Antimicrobial Resistance event, organised by Wellcome in partnership with the UK, Ghanaian and Thai governments and the UN Foundation.
The results from our workshop exploring the use of clinical trial networks for antibiotic development and why they’re important.
We propose concrete interventions to combat the real and growing threat of antimicrobial resistance.
The current language used to describe controlled human infection models is complex, with many different names being used. This report highlights what the issues and possible solutions are.